Elmind Capital LP purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 452,340 shares of the company’s stock, valued at approximately $26,294,524,000. Vaxcyte makes up 6.6% of Elmind Capital LP’s holdings, making the stock its 5th biggest holding. Elmind Capital LP owned about 0.30% of Vaxcyte at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in PCVX. NEXTBio Capital Management LP bought a new position in shares of Vaxcyte in the fourth quarter worth $4,406,000. Norges Bank acquired a new stake in Vaxcyte during the fourth quarter worth about $56,703,000. Universal Beteiligungs und Servicegesellschaft mbH grew its stake in Vaxcyte by 105.3% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 70,124 shares of the company’s stock worth $3,236,000 after buying an additional 35,974 shares in the last quarter. Candriam S.C.A. bought a new position in Vaxcyte in the 1st quarter valued at about $18,306,000. Finally, Bank of America Corp DE raised its position in shares of Vaxcyte by 73.4% in the 1st quarter. Bank of America Corp DE now owns 1,216,843 shares of the company’s stock valued at $70,711,000 after buying an additional 515,209 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on PCVX. Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $86.00.
Insider Transactions at Vaxcyte
In other news, CEO Grant Pickering sold 22,461 shares of Vaxcyte stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $52.50, for a total transaction of $1,179,202.50. Following the transaction, the chief executive officer owned 474,703 shares in the company, valued at approximately $24,921,907.50. The trade was a 4.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00. Following the completion of the sale, the chief financial officer directly owned 104,395 shares in the company, valued at approximately $5,979,745.60. This represents a 8.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 120,646 shares of company stock worth $6,570,810. 3.30% of the stock is owned by corporate insiders.
Vaxcyte Stock Performance
Shares of PCVX opened at $61.09 on Wednesday. Vaxcyte, Inc. has a 52 week low of $29.87 and a 52 week high of $65.00. The stock has a market capitalization of $9.09 billion, a price-to-earnings ratio of -8.01 and a beta of 1.23. The stock has a fifty day moving average of $56.91 and a 200-day moving average of $55.88.
Vaxcyte (NASDAQ:PCVX – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same period last year, the firm posted ($1.22) earnings per share. As a group, equities analysts forecast that Vaxcyte, Inc. will post -7.6 EPS for the current year.
Vaxcyte Company Profile
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Featured Stories
- Five stocks we like better than Vaxcyte
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVX – Free Report).
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
